Physiomics PLC (AIM:PYC) has appointed Mark Davies as Head of Quantitative Pharmacology and Data Science in a newly created role.
Davies brings over 20 years of experience in drug development at major pharmaceutical companies (such as AstraZeneca) and biopharma servicing businesses worldwide with key specialities of computational biology and data informatics.
More recently, he has worked in business development roles for state-funded (Medicines Discovery Catapult) and multiple Contract Research Organisations (service providers) across Europe.
Davies will be responsible for the company's modelling, simulation and data science service line and will work closely on overall strategic direction.
Peter Sargent, Physiomics’ chief executive, commented: "We are delighted to welcome Mark to our team.
“We feel that with his unique mix of technical and commercial experience spanning across modelling & simulation, data science and drug development, he will be a great addition to the company".